BioSpace News Archive

Tachyon Therapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase 1 clinical study of TACH101 in patients with advanced solid tumors.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the publication of a peer-reviewed article of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a case review in Molecular Therapy of the single patient treated with ALLO-501A who presented with a chromosomal rearrangement.

Inozyme Pharma, Inc. (Nasdaq: INZY) today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, from 2:10-3:10pm ET in Boston.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that it has begun commercial shipping of its Viality™ with AuraClens™ fat transfer system.

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

Dyadic International, Inc. today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, will be participating at the following investor and industry events.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced that it has achieved a major milestone in its efforts to deliver commercial-scale production of the scarce therapeutic radioisotope actinium-225 (Ac-225).

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced the first subject has been treated in Italy in the Company’s Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) for the treatment of subjects with AML who are refractory to or relapsed after induction therapy (MB-106).